Decitropine is an anticholinergic and antiulcer agent, developed by Koninklije Pharma FAB NV in the 1960s.

Homprenorphine is an opioid receptor agonist with opioid analgesic activity. This compound has never been marketed.

Norgesterone (norvinodrel, vinylestrenolone) is a progestin medication which was formerly used in birth control pills for women. The compound shows no androgenic and very little estrogenic activity; its progestational effect, as well as other properties, suggests its use as claudogenic agent. Norgesterone is an agonist of the progesterone receptor. It was used in combination with ethinylestradiol in birth control pills to prevent pregnancy.

Nitrocycline is a tetracycline antibiotic.

Dacuronium is an aminosteroid, acting as a competitive antagonist of nicotinic acetylcholine receptors. In animals, dacuronium worked as a short-acting muscle relaxant with a rapid onset of action. In a clinical trial, dacuronium was markedly less potent than tubocurarine and did not show a rapid recovery from its action.

Cloximate is a non-steroidal anti-inflammatory drug, developed in the Dutch company Philips-Duphar B.V. Research Laboratories in the 1970s. Cloximate acts by inhibition of PGE2 biosynthesis. In preclinical experiments, cloximate showed good inhibitory activities in local exudative tests, in the proliferative and functional aspects of experimental inflammation, as well as in the bradykinin-evoked bronchoconstriction test. Cloximate showed almost no harmful effects on the gastrointestinal mucosa and no influence upon the emptying rate of the stomach. Cloximate was evaluated in double-blind clinical trials, where different formulations were compared with naproxen. Gastrointestinal blood loss increased more in the naproxen group than in the group treated with non-enteric coated cloximate.

Cortisuzol is a glucocorticoid corticosteroid, discovered by the French company Roussel Uclaf, and claimed to have anti-inflammatory activity in a number of clinical case reports.

LEMIDOSUL is a loop diuretic, antihypertensive agent.

LAFLUNIMUS is an immunomodulator with anti-inflammatory activities. It inhibits prostaglandin endoperoxide H synthases 1 and 2 in vitro and in vivo. It also acts as an immunosuppressive agent being an inhibitor of mitochondrial dihydroorotate dehydrogenase and concomitant reducing agent of pyrimidine nucleotide pools.

Leurubicin was developed as a prodrug of doxorubicin (Dox) with the aim of lowering the cardiotoxicity and improving the therapeutic index produced by Dox. Antineoplastic agent Dox was rapidly formed from leurubicin, reaching peak levels in plasma within 5 min and in tissues within 1 h after i.v. administration of leurubicin. The incorporation of leurubicin into the MES-SA human uterine sarcoma cell line and its Dox resistant counterpart, MES-SA/Dx5 cell line and the subsequent transformation of leurubicin into Dox and its subcellular distribution, were investigated. In both cell lines the cellular uptakes of Dox and leurubicin were similar at equimolar doses, while the percent transformation of leurubicin into Dox in MES-SA/Dx5 cells was about twice as great as its transformation in MES-SA cells, which is beneficial for reaching Dox cytotoxic levels in this resistant cell line. The highest Dox/ leurubicin ratio was found in the nuclear fraction, followed by the ratio in the low density organelle fraction that contains lysosomes, organelles in which lysosomal hydrolytic enzymes, capthesins, transform leurubicin into Dox.